Genetic Testing for ADHD Medications: What Your DNA Can and Cannot Tell You

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental conditions, affecting both children and adults. ADHD medications fall into two broad categories: stimulants (methylphenidate, amphetamine) and non-stimulants (atomoxetine, guanfacine, clonidine). Of these, pharmacogenomics is currently most relevant to atomoxetine — the only ADHD medication with a published CPIC guideline.

This article explains what genetic testing for ADHD medications can and cannot tell you about treatment, which genes are relevant, and how to interpret results in the context of ADHD management. For the full picture of pharmacogenomics from consumer DNA data, see our complete guide to pharmacogenomics from raw DNA data.

Atomoxetine: The Key ADHD-Pharmacogenomics Connection

Atomoxetine (Strattera) is a non-stimulant ADHD medication that works by inhibiting norepinephrine reuptake. It is almost exclusively metabolized by the CYP2D6 enzyme, making it one of the most genotype-sensitive medications in clinical use.

In CYP2D6 poor metabolizers, atomoxetine plasma levels can be approximately 10 times higher than in normal metabolizers at the same dose. The half-life extends from roughly 5 hours to 21 hours. This dramatic difference is why CPIC has published a Level A guideline — the strongest evidence category — recommending dose adjustments for poor metabolizers.

For more details on dosing recommendations by metabolizer status, see our dedicated atomoxetine pharmacogenomics page.

CYP2D6: The Gene That Matters for Atomoxetine

The CYP2D6 gene is the most polymorphic drug-metabolizing gene, with over 130 identified allelic variants. Your CYP2D6 metabolizer phenotype — ultrarapid, normal, intermediate, or poor — is determined by the combination of variants you carry.

CYP2D6 poor metabolizer frequency varies by population: approximately 5–10% in European populations, 1–3% in East Asian and African populations. If you are a CYP2D6 poor metabolizer and take atomoxetine, your prescriber may consider starting at a lower dose and titrating slowly.

Note that CYP2D6 is also relevant to many antidepressants and antipsychotics. If you or your child takes both ADHD medication and an antidepressant, your CYP2D6 status may be relevant to both. See our CYP2D6 and antidepressants guide for the full picture.

Why Stimulant ADHD Medications Don't Have Pharmacogenomic Guidelines

Stimulant medications — methylphenidate (Ritalin, Concerta), amphetamine (Adderall, Vyvanse), and lisdexamfetamine — are the most commonly prescribed ADHD treatments. However, they are not primarily metabolized by CYP2D6 or CYP2C19, the two pharmacogenes with the strongest clinical evidence.

• Methylphenidate is metabolized primarily by carboxylesterase 1 (CES1), not by CYP enzymes. While some research has explored CES1 variants, there are no CPIC guidelines.
• Amphetamine and lisdexamfetamine are metabolized through multiple non-CYP pathways. Pharmacogenomic evidence is insufficient for clinical guideline development at this time.

This does not mean genetics play no role in stimulant response — it means current evidence is not strong enough for standardized gene-based dosing recommendations. As research evolves, new guidelines may emerge.

What Pharmacogenomics CAN Tell You About ADHD Treatment

• Atomoxetine metabolism rate: Whether your body processes atomoxetine faster or slower than expected, which affects drug levels at standard doses.
• Dose adjustment guidance: CPIC provides specific recommendations for atomoxetine dosing in CYP2D6 poor metabolizers.
• Broader medication context: If you also take antidepressants or other psychiatric medications, your CYP2D6 and CYP2C19 metabolizer status may be relevant across multiple drugs. The Psychiatric Medication Report covers these interactions together.

What Pharmacogenomics CANNOT Tell You

• It cannot predict ADHD medication effectiveness. Pharmacogenomics shows how your body metabolizes a drug — not whether it will improve your focus, attention, or executive function.
• It does not apply to most stimulant medications. Methylphenidate, amphetamine, and lisdexamfetamine do not have CPIC-level pharmacogenomic evidence.
• It does not diagnose ADHD. Pharmacogenomic testing analyzes drug metabolism, not neurodevelopmental conditions.
• It does not account for all factors in treatment response. ADHD medication effectiveness is influenced by many factors including coexisting conditions, behavioral interventions, sleep, and treatment adherence.

Using Consumer DNA Data for ADHD Pharmacogenomics

If you have raw DNA data from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA, your file contains many of the CYP2D6 variants needed for atomoxetine pharmacogenomic analysis.

Consumer arrays include SNP variants that define common CYP2D6 star alleles, but cannot detect gene deletions (*5) or duplications. This means some poor metabolizers and ultrarapid metabolizers may not be identified from consumer data alone. See our limitations page for details, or learn what to do with your 23andMe raw data.

ADHD and Comorbid Conditions

ADHD frequently co-occurs with depression, anxiety, and other psychiatric conditions. Many people with ADHD take both a stimulant or atomoxetine and an antidepressant. In these cases, pharmacogenomic testing becomes relevant across multiple medications:

• CYP2D6 status affects atomoxetine, paroxetine, fluoxetine, venlafaxine, nortriptyline, and many antipsychotics.
• CYP2C19 status affects escitalopram, sertraline, citalopram, and several tricyclic antidepressants.

DecodeMyBio's Psychiatric Medication Report covers both CYP2D6 and CYP2C19 interactions across ADHD medications, antidepressants, and antipsychotics — providing a unified view for patients managing multiple conditions. See our depression pharmacogenomics guide for the antidepressant perspective.